Runben Biotechnology Co

Runben Biotechnology Co Liabilities

The The Liabilities of Runben Biotechnology Co (603193.SS) as of Oct 17, 2026 is 116.79 M CNY. In the previous year, The Liabilities was 138.88 M CNY — a change of -15.91% (lower).

Liabilities

116.79 MCNY

YoY

-15.91%

Last updated:

In 2025, Runben Biotechnology Co's total liabilities amounted to 116.79 M CNY, a -15.91% difference from the 138.88 M CNY total liabilities in the previous year.

The Runben Biotechnology Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
27.07 M CNY
Jan 1, 2020
26.33 M CNY
Jan 1, 2021
84.69 M CNY
Jan 1, 2022
102.83 M CNY
Jan 1, 2023
97.61 M CNY
Jan 1, 2024
138.88 M CNY
Jan 1, 2025
116.79 M CNY
The Runben Biotechnology Co Liabilities history
YEARLiabilitiesYoY
116.79 MCNY-15.91%
138.88 MCNY+42.28%
97.61 MCNY-5.08%
102.83 MCNY+21.42%
84.69 MCNY+221.67%
26.33 MCNY-2.74%
27.07 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co Ltd, trading under the ticker symbol 603193.SS and identified by ISIN CNE100006DK5, is a Chinese enterprise operating within the Consumer Staples sector, specifically in the consumer products industry. Headquartered in Guangzhou, Guangdong, the company has established itself as a specialized manufacturer and distributor of personal care items, with a notable focus on mosquito repellents and baby care solutions. As of the latest available data, the firm employs 917 full-time staff members who support its extensive research, development, manufacturing, and sales operations. Runben Biotechnology officially entered the public markets via an initial public offering on October 17, 2023, marking a significant milestone in its corporate development and providing greater visibility into its financial and operational strategies. The company’s product portfolio is strategically divided into three primary categories: mosquito repellent products, baby care products, and essential oil-based items. Among its best-selling offerings are electric mosquito repellent liquids and DEET-based repellent solutions, which cater to the growing consumer demand for effective and safe pest control measures. In the personal care segment, the firm produces a diverse range of skincare and hygiene products, including lipsticks, face creams, facial cleansers, and general skincare creams, targeting consumers who prioritize gentle and specialized formulations. The company’s business model relies heavily on digital commerce channels, utilizing internet sales platforms to reach its customer base directly. This includes online direct sales, distribution through major online platforms, and agency sales models that facilitate broader market penetration. By leveraging these e-commerce strategies, Runben Biotechnology has been able to maintain a strong presence in the domestic Chinese market, where the majority of its revenue is generated. The firm’s commitment to innovation in product formulation, combined with its agile distribution network, positions it as a competitive player in the crowded consumer goods landscape. Through its continued investment in research and development, the company aims to expand its product lines and enhance the quality of its offerings, ensuring it meets the evolving needs of modern consumers. The integration of traditional manufacturing expertise with modern digital sales tactics allows Runben Biotechnology to adapt quickly to market trends and maintain customer loyalty. As it continues to grow, the company remains focused on delivering high-quality, safe, and effective products that address everyday consumer concerns, particularly in the areas of personal hygiene and family care. Runben Biotechnology Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Runben Biotechnology Co's Liabilities

Runben Biotechnology Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Runben Biotechnology Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Runben Biotechnology Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Runben Biotechnology Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Runben Biotechnology Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Runben Biotechnology Co stock

The Liabilities of Runben Biotechnology Co is 116.79 M CNY in 2025.

The Liabilities of Runben Biotechnology Co changed from 138.88 M CNY to 116.79 M CNY, representing a -15.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Runben Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Runben Biotechnology Co

All Key Metrics — Runben Biotechnology Co